MARA raises $23m to build Africa’s crypto economy

Published by
Business Day

MARA, a Pan-African crypto exchange has announced a $23 million in funding to build Africa’s crypto economy. Backed by Coinbase Ventures, Alameda Research (FTX), Distributed Global, TQ Ventures, DIGITAL, Nexo, Huobi Ventures, Day One Ventures, Infinite Capital, DAO Jones and more, Mara has announced a partnership with the Central African Republic to become its official […] read more MARA raises $23m to build Africa’s crypto economy Continue reading “MARA raises $23m to build Africa’s crypto economy”

Lors de la Journée internationale des familles, Angel Yeast encourage les ménages à cuisiner.

YICHANG, Chine, 16 mai 2022 /PRNewswire/ — Angel Yeast (en.angelyeast.com, SH600298), un fabricant international de levure et d’extraits de levure coté en bourse, a annoncé lors de la Journée internationale des familles (15 mai) la poursuite de son engagement de longue date à soutenir et promouvoir un mode de vie sain pour les familles du monde entier. En proposant une large gamme de produits à base de levure, l’entreprise entend inspirer et encourager les foyers urbains à cuisiner davantage.

International Day of Families, Angel Yeast encourages households to bake at home.

L’une des missions de la Journée internationale des familles étant de sensibiliser au bien-être des familles, Angel Yeast espère commencer par la gastronomie pour créer des discussions à l’échelle mondiale sur la manière d’avoir un mode de vie plus sain et plus durable, selon Xishan Wang, directeur général adjoint d’Angel Yeast.

« Ces dernières années, nous avons constaté que le nombre de gens qui cuisinent avait diminué. En effet, la vie moderne et l’ère numérique ont créé davantage d’options de restauration. Les jeunes, en particulier, n’ont pas envie de cuisiner, ce qui suscite des inquiétudes quant à la sécurité alimentaire, la nutrition, la pollution due aux emballages plastiques, ainsi qu’un manque de liens et d’ambiance familiale », a déclaré Wang.

Angel Yeast a joué un rôle de premier plan dans la consommation familiale de produits à base de levure en Chine. La société est progressivement devenue un fournisseur majeur sur le marché mondial. Les produits d’Angel Yeast sont utilisés par des millions de familles dans le monde dans la fabrication du pain, du naan, du baozi (petit pain farci à la vapeur) et de nombreuses autres pâtisseries.

Pour aider et encourager les gens à cuisiner des plats faits maison, Angel Yeast a fait imprimer des codes QR sur certains emballages de ces produits. En les scannant, les consommateurs peuvent accéder à une vidéo de recette éducative. Il existe également toute une série de programmes de formation au fait maison pour les familles organisés par Angel Yeast dans le monde entier, visant tous à créer des opportunités pour les familles de passer plus de temps ensemble.

En outre, Angel Yeast a intensifié ses efforts en matière d’innovation de produits afin d’offrir davantage d’options de régimes alimentaires nutritifs aux familles. Les lignes de produits comprennent :

  • Boulangerie : Angel Yeast a développé une gamme de préparations pour faire du pain et de gâteaux sains et nutritifs. En outre, ses agents de levage sans aluminium sont largement utilisés en Chine.
  • Arôme YE (extrait de levure) : L’arôme YE est un arôme naturel qui peut sublimer les saveurs et réduire la consommation de sels. Grâce aux efforts d’Angel Yeast, 90 % des sauces soja à teneur réduite en sel en Chine contiennent de l’extrait de levure.
  • Santé : La levure contient des substances nutritives pour les êtres humains. Angel Yeast a innové la technologie des protéines de levure pour produire des produits de soins de santé, médicaux et cosmétiques.
  • Brassage et distillation à domicile : Une autre ligne de produits clés d’Angel Yeast comprend des produits de levure pour la fabrication de bière, de vin et de baijiu (alcool de riz) à domicile et la distillation.

À propos d’Angel Yeast

Fondée en 1986, Angel Yeast Co., Ltd est spécialisée dans la production de levure et de dérivés de levure. Sa gamme de produits comprend la levure et les ingrédients boulangers, les dim sum et les assaisonnements chinois, les extraits de levure salée, les spiritueux distillés et les biocarburants, les enzymes, et des solutions pour la santé humaine, la nutrition animale, la nutrition végétale, et la nutrition microbienne. À l’heure actuelle, Angel Yeast dispose de 12 bases de production avancées internationales en Chine, en Égypte et en Russie, et fournit des produits et services à plus de 160 pays et régions du monde entier.

Photo – https://mma.prnewswire.com/media/1817357/image.jpg

Logo – https://mma.prnewswire.com/media/1586948/angel_logo_Logo.jpg

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

“The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the treatment paradigm for TED patients in China.”

ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of TED. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids.

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater area of China from Viridian Therapeutics, Inc. (Viridian) in October 2020. In October 2021, Viridian submitted an IND for VRDN-001 to the U.S. Food and Drug Administration and in December 2021 initiated a Phase 1/2 clinical trial to evaluate proof of concept in TED patients in North America.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma soumet une demande en Chine pour un nouveau médicament expérimental pour ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne

WALTHAM, Massachusetts et SHANGHAI, Chine, 16 mai 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le besoin dans le monde entier, a annoncé aujourd’hui la soumission d’une demande pour un nouveau médicament expérimental (IND) à la China National Medical Products Administration (NMPA ou Administration nationale des produits médicaux de la Chine) pour le lancement d’une étude clinique de phase 1/2 sur ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne (TED). Cette étude vise à évaluer l’innocuité, la tolérance, la pharmacocinétique et l’efficacité préliminaire de ZB001.

« La soumission de l’IND auprès de la NMPA pour pour ZB001 marque une étape importante pour Zenas », a déclaré Hua Mu, MD, PhD, président-directeur général de Zenas. « Il n’existe actuellement aucun traitement approuvé pour les patients atteints de TED en Chine. Les options de traitement sont limitées et impliquent souvent des doses élevées de stéroïdes associées à des effets secondaires graves ou à une intervention chirurgicale. ZB001 a le potentiel de changer le paradigme de traitement pour les patients atteints de TED en Chine. »

ZB001 est un anticorps monoclonal humanisé différencié ciblant le récepteur du facteur de croissance analogue à l’insuline 1 (IGF-1R) pour le traitement de la TED. La TED est une maladie auto-immune invalidante qui provoque une inflammation et une fibrose dans l’orbite de l’œil, ce qui peut causer une vision double, des douleurs et une cécité potentielle. Les patients gravement atteints ont souvent besoin de plusieurs interventions chirurgicales correctives sur l’orbite, les muscles oculaires et les sourcils.

En octobre 2020, Zenas BioPharma a acquis auprès de Viridian Therapeutics, Inc. (Viridian) les droits exclusifs de développement, de fabrication et de commercialisation de ZB001 et d’autres composés ciblant l’IGF-1R dans les indications non oncologiques dans la Grande Chine. En novembre 2021, Viridian a déposé une demande d’IND pour ZB001 (appelé VRDN-001 par Viridian) auprès de la Food and Drug Administration des États-Unis et a lancé en décembre 2021 un essai clinique de phase 1/2 visant à évaluer la preuve de concept chez les patients atteints de TED aux États-Unis.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma solicita aprovação do medicamento investigacional ZB001 na China para o tratamento de Doença Ocular da Tireoide

WALTHAM, Mass. e XANGAI, China, May 15, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas para pacientes necessitados em todo o mundo, anunciou hoje que solicitou a aprovação de um novo investigacional (IND) à Administração Nacional de Produtos Médicos da China (NMPA) para o início de um estudo clínico de Fase 1/2 do ZB001 para o tratamento da Doença Ocular da Tireoide (TED). Este estudo foi projetado para avaliar a segurança, tolerabilidade, farmacocinética e eficácia preliminar do ZB001.

“A solicitação de aprovação do ZB001 IND ao NMPA é um marco significativo para a Zenas”, disse Hua Mu, MD, PhD, Diretor Executivo da Zenas. “No momento não existe nenhuma terapia aprovada para pacientes com TED na China. As opções de tratamento são limitadas e muitas vezes envolvem altas doses de esteroides que resultam em efeitos colaterais graves ou intervenção cirúrgica. O ZB001 tem o potencial de mudar o paradigma do tratamento para pacientes com TED na China.”

O ZB001 é um anticorpo monoclonal humanizado diferenciado que direciona o receptor de fator de crescimento semelhante à insulina 1 (IGF-1R) para o tratamento de TED. TED é uma doença autoimune debilitante que causa inflamação e fibrose dentro da órbita do olho, podendo causar visão dupla, dor e cegueira em potencial. Pacientes com doença grave muitas vezes requerem múltiplas cirurgias corretivas da órbita, músculos dos olhos e pálpebras.

A Zenas BioPharma licenciou os direitos exclusivos para desenvolver, fabricar e comercializar o ZB001 e outros compostos direcionados ao IGF-1R em indicações não oncológicas na Grande China da Viridian Therapeutics, Inc. (Viridian) em outubro de 2020. Em novembro de 2021, a Viridian solicitou um IND para o ZB001 (VRDN-001 na Viridian) à Food and Drug Administration dos EUA e, em dezembro de 2021, deu início a um ensaio clínico de Fase 1/2 para avaliar a prova de conceito em pacientes com TED nos EUA.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

 

Tunisia rescues 81 migrants headed to Europe from Libya

TUNIS— The Tunisian navy said it rescued 81 migrants, one of them a woman, who had set out for Europe from Libya on a barely seaworthy vessel.

The boat, which had been damaged, was boarded around six kilometres off Tunisia’s northeastern coast, the navy said.

It carried 38 Egyptians, 32 Bangladeshis, 10 Sudanese and a Moroccan, all aged between 20 and 38, who had set off from the coastal village of Abu Kammash, close to Libya’s border with Tunisia, according to what they told officers.

They were handed over to the national guard for processing.

Tunisia and neighbouring Libya are key departure points for migrants seeking to reach European shores, often in poorly-maintained vessels.

The Italian island of Lampedusa is only about 130 kilometres from the Tunisian coast.

Last month, Libyan authorities arrested 542 would-be migrants preparing to depart for Europe in inflatable boats, a security source said. Most were originally from Bangladesh.

The International Organization for Migration has said that nearly 2,000 migrants drowned or went missing in the Mediterranean in 2021, compared to 1,401 the previous year.

It is the world’s deadliest migration route, but people hoping to build a better life in Europe increasingly risk it.

Source: NAM NEWS NETWORK

Kenyan fighting FGM crowned World’s Best Nurse

NAIROBI— A Kenyan nurse who campaigns against early marriage and female genital mutilation says she is “speechless” after winning a prize of $250,000.

Anna Qabale Duba’s colleagues say she always goes the extra mile for others in her pastoralist community in the northern county of Marsabit, and runs a school in her village.

“This award will help me to expand my school all over Kenya,” she said.

In the morning the classrooms of Torbi Pioneer Academy host lessons for children, before their parents come in for literacy classes in the afternoons – and sometimes both age groups get the same homework.

Qabale says she was the only university-educated girl from Torbi village, and the only girl educated past primary school level in her family of 19 children.

The 31-year-old now holds a Masters in Epidemiology and has set up a foundation aimed at empowering young girls and mothers.

“I am so passionate about education. After tasting the fruits of education, I decided to go back home to empower the rest,” she said.

Family and community are key influences – and Qabale has dedicated her latest nursing award to her late brother, who part-funded her university studies.

Through her Qabale Duba Foundation, the school she has built in her village also teaches parents about key sexual and reproductive health issues.

Working as a nurse at Marsabit County Referral Hospital, she strives to end harmful cultural practices such as female genital mutilation (FGM) and early marriage, and it is for her work in these areas that Dubai-based Aster DM healthcare says she beat more than 24,000 nominees to their Global Nursing Award.

“It’s not easy to talk about these things publicly. Being a woman – and we come from our patriarchal families – it’s not easy to talk about them, but I am really trying my level best,” Qabale said.

“I am using education as an excuse for my advocacy work to campaign against these devices.”

‘I escaped forced marriage aged 14’

The married mother-of-one’s personal experiences have shaped her convictions.

“I underwent female genital mutilation at the age of 12 and I narrowly escaped early forced marriage at the of 14,” she said.

Even though FGM is illegal in Kenya, around 91% of girls and young women are subjected to it in the country’s northern regions, according to the Kenyan Anti-FGM board.

Parents and guardians often take their daughters across the border into neighbouring countries to escape Kenya’s stringent laws.

Colleagues say Qabale’s drive has seen women and girls become more aware of their healthcare rights.

“She knows all too well the challenges that young girls face,” Hassan Halakhe, director of preventive promotion health services at Marsabit County Referral Hospital, said.

“Many of them now do not miss out on classes as they are given sanitary towels to use when they are on their menses. They are also taught how to make reusable pads.”

Thursday’s ceremony in Dubai was Ms Qabale’s second high-profile gong, having won the Global Citizens’ People’s Choice Award in New York in 2019.

Kenya’s Health Minister Mutahi Kagwe praised Ms Qabale’s “hard work and her fearless spirit”, while Marsabit County Referral Hospital Director Liban Wako says “this award means so much to young girls in Marsabit – that they too can achieve their dreams.”

Source: NAM NEWS NETWORK

Covid-19: South Africa urges agencies to buy Africa-made vaccines as low demand hit manufacturers

PRETORIA— South Africa’s President Cyril Ramaphosa has urged international organisations and donor agencies to buy Covid vaccines from African manufacturers.

President Ramaphosa said this would “ensure the developing capabilities on the continent are retained”, while speaking to a global summit on Covid.

“International agencies that have had a lot of money donated to (them) for purchasing and procuring vaccines for developing-economy countries are not buying vaccines from African vaccine manufacturers, even for those vaccines that are destined for African countries,” he said.

It comes as a vaccine manufacturer in South Africa risks stopping production for lack of orders.

Aspen Pharmacare recently said that it may have to stop production in its South African plant after being hit by low demand.

The company negotiated a licensing deal in November to package and sell Johnson & Johnson’s vaccine for distribution across Africa.

It was seen as a boost for vaccine production and distribution across Africa. However, the continent still has a low vaccination rate even as it faces a new wave of the virus.

Fewer than one in six Africans have had two doses of a coronavirus vaccine, with many reluctant to get jabbed.

On Thursday, Ramaphosa said his country was still advocating for an intellectual property waiver to improve global access to vaccines.

Source: NAM NEWS NETWORK

Nigeria student killing: Round-the-clock curfew in Sokoto after protests

SOKOTA (Nigeria)— A 24-hour curfew has been declared in Sokoto, north-west Nigeria, after protesters took to the streets demanding the release of two suspects in the murder of a Christian student last week.

Deborah Samuel was beaten and burned by Muslim students who accused her of posting “blasphemous” statements about Islam in a WhatsApp group on Thursday.

Her death has been widely condemned by Muslims and Christians across Nigeria.

On Saturday, demonstrators burned tyres and the police fired teargas.

Some of the protesters besieged the palace of the Muhammad Sa’ad Abubakar, the Sultan of Sokoto and the highest spiritual figure among Muslims in Nigeria.

The Sultan has condemned the killing at Shehu Shagari College of Education and demanded those involved face justice.

Announcing the curfew, Sokoto Governor Aminu Waziri Tambuwal urged the protesters: “Please, in the interest of peace go back home.”

Nigeria is Africa’s most-populous country and most people in its mainly Muslim north and the largely Christian south are deeply religious.

Religious tensions and deadly clashes are not uncommon, particularly in the north where some states have adopted strict sharia laws, including death sentences for blasphemy.

Blasphemy in Islam includes the mocking or disparaging of attributes of the religion as well as denying any of its fundamental beliefs.

President Muhammadu Buhari has condemned Samuel’s killing and said there should be an impartial investigation.

Nigeria’s largest grouping of Christian churches has demanded the authorities bring the culprits to justice.

Source: NAM NEWS NETWORK